EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/15/2025
Back to search
Official data from USPTO
ULTRAGENYX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000097980518Class
1, 5, 16, 36, 41, 42, 44
Filing
97980518
Registration
7907676
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
09/16/2025
Trademark type
Combined
Nice classes
1, 5, 16, 36, 41, 42, 44
Filing date
12/21/2022
Registration date
08/19/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/19/2025
Last transaction
09/16/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2017-11-00
First use in commerce
2017-11-00
Drawing code
5
Owner type
03
Owner location
Novato, CA
Examiner
HELLMAN, ELI
Law office
L20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "ultragenyx" in a lower-case stylized font.
Holders and representatives
Holders
Ultragenyx Pharmaceutical Inc.
Representatives
Brian Focarino Cooley LLP
Technical classification
Nice Classes
Class 1Class 5Class 16Class 36Class 41Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiologicalbiochemical preparations for use in gene delivery technologynucleic acidsincludingcoding and non-coding deoxyribonucleic acidsplasmidsvectorspromotorsenhancers and other regulatory sequencesfor use in vitro laboratory use; chemicalbiologicalbiochemical preparations for use in the manufacture of pharmaceutical preparations
Class 5
Pharmaceutical preparations for the treatment of liverhepatologicalcardiovascularcentral nervous systeminflammatoryautoimmunemusculoskeletalophthalmologicrespiratoryosteopathiconcologicendocrineorthopedicmetaboliclipid-relatedgeneticneuromuscularautosomallysosomal storageenzymehematologic and long-chain fatty acid oxidation disorders (LC-FAOD) diseases and disorders; chemicalbiologicalbiochemical preparations for use in gene delivery technology for medical usenucleic acidsincluding coding and non-coding deoxyribonucleic acidsplasmidsvectorspromotorsenhancers and other regulatory sequencesfor use in in vivo therapeutic use in gene therapy
Class 16
Printed publicationsbooksbrochuresinformational pamphletsinformational cardsadvertisements being signs and boards of paper in the field of rare diseases and disorders
Class 36
Financial and insurance consultation servicespatient advisorysupport and consultancy services regarding patient financesinsurance and access to medical treatment; providing financial and insurance informationproviding information and guidance in connection with health insurance benefit plans and other patient financial assistance resources; financial and insurance consultation servicesinsurance and medical and pharmaceutical access consultation servicesassisting patients and their caregivers to identify the scope of coverage offered by patient medical and pharmaceutical insurance and to identify other financial assistance resources for payment of patient treatment; insurance consultation servicesassisting patients and their caregivers to obtain authorization and payment for medical and pharmaceutical costs
Class 41
Education and training servicesseminarsproviding non-downloadable webinarsworkshops for healthcare professionalscaregiverspatientsproviders in the field of rare diseases and disorders; online journalsblogs featuring information on rare diseases and disorders
Class 42
Pharmaceuticalscientificmedical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editinggene editinggenome engineeringgene modulationgenetic diseasesgene therapycell therapy; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; product development in the fields of genetic therapies and effectors to regulatemodulatecharacterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; scientific and medical researchcompiling and sharing of patient data for research purposes in the field of rare diseases and disorders; medical and scientific research information in the field of rare diseases and disorders; computer servicescreating an on-line community for registered users to obtain feedback from their peersinteract with research datashare data in the field of rare diseases and disorders; pharmaceutical research servicesrecruitment of rare disease patients for panels such as pharmaceutical research panels; providing medical research and scientific research information in the field of hypophosphatemia
Class 44
Providing medical servicesgene therapy design and delivery services being gene therapy medical services in the field of liverhepatologicalcardiovascularcentral nervous systemendocrineinflammatorymetabolicautoimmunemusculoskeletalneurologicalophthalmologicrespiratoryhematologic diseases and disorders; medical consulting services in the field of rare diseases and disorders; healthcare servicesproviding an online database of medical and healthcare information in the field of rare diseases and disorderscollecting data and information on rare diseases and disorders for screeningdiagnosis and treatment purposes; medical information services in the nature of providing a database in the field of hypophosphatemia information based on collected patient data and information all for treatment and diagnostic purposes
Publications
History of USPTO decisions and trademark events.
37 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/19/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
08/19/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/31/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/31/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/29/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
07/29/2025
EX2G
SOU EXTENSION 2 GRANTED
07/29/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/24/2025
IUAF
USE AMENDMENT FILED
01/16/2025
DRRR
DIVISIONAL REQUEST RECEIVED
01/16/2025
EXT2
SOU EXTENSION 2 FILED
01/16/2025
EISU
TEAS STATEMENT OF USE RECEIVED
01/16/2025
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
01/16/2025
EEXT
SOU TEAS EXTENSION RECEIVED
01/16/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
08/02/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/02/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/02/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/02/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/02/2024
EX1G
SOU EXTENSION 1 GRANTED
08/02/2024
EXT1
SOU EXTENSION 1 FILED
08/02/2024
EEXT
SOU TEAS EXTENSION RECEIVED
08/02/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/06/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/12/2023
PUBO
PUBLISHED FOR OPPOSITION
12/12/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/22/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/03/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/25/2023
GNRT
NON-FINAL ACTION E-MAILED
09/25/2023
CNRT
NON-FINAL ACTION WRITTEN
09/25/2023
DOCK
ASSIGNED TO EXAMINER
09/21/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/18/2023
NWAP
NEW APPLICATION ENTERED
12/24/2022
Continuous trademark protection
Get notified about every new filing that threatens ULTRAGENYX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.